0. DOCID:30672 SCORE: 0.00226190130579264
DOCNO: 11823691
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: adverse effects
QUALIFIER: adverse effects
QUALIFIER: analogs & derivatives
QUALIFIER: chemically induced
AUTHOR: Manuel F Rosado MF
AUTHOR: Daniel H Kett DH
AUTHOR: Roland M H Schein RM
AUTHOR: Francisco J Baraona FJ
AUTHOR: Kasi S Sridhar KS
AFFILIATION: Department of Medicine, Jackson Memorial Hospital, University of Miami School of Medicine, 1611 NW 12th Avenue, Miami, FL 33136-1094, U.S.A.
PUBTYPE: Case Reports
PUBTYPE: Journal Article
JOURNALTITLE: American journal of clinical oncology : the official publication of the American Radium Society.
COUNTRY: United States
TITLE: Severe pulmonary toxicity in a patient treated with gemcitabine.
PUBDATE: 20020201
Gemcitabine is a pyrimidine analog of deoxycytidine with activity against nonhematologic and hematologic malignancies. Its pulmonary toxicity is usually mild and self-limiting. We describe a male patient with lung cancer in whom severe dyspnea and interstitial infiltrates developed after the administration of gemcitabine.


1. DOCID:30666 SCORE: 0.00226190090317772
DOCNO: 12113243
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: methods
QUALIFIER: therapeutic use
QUALIFIER: diagnosis
QUALIFIER: enzymology
QUALIFIER: analysis
QUALIFIER: antagonists & inhibitors
QUALIFIER: analysis
QUALIFIER: antagonists & inhibitors
AUTHOR: L Austin Doyle LA
AUTHOR: W Edward Highsmith WE
AFFILIATION: Greenebaum Cancer Center, 22 South Greene Street, Baltimore, MD 21201, USA. adoyle@umm.edu
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: Expert review of anticancer therapy.
COUNTRY: England
TITLE: Telomerase as a diagnostic and therapeutic target for cancer.
PUBDATE: 20020401
Telomerase is a ribonucleoprotein enzyme responsible for the elongation of telomeres at the ends of chromosomes. It is widely expressed in most cancers, while absent from most normal somatic cells. Telomerase is partially responsible for the cellular immortalization that allows human cancers to progress indefinitely. Due to its widespread occurrence in cancer and its crucial role in the maintenance of the tumor, telomerase is an attractive target for cancer diagnosis and treatment.


2. DOCID:31904 SCORE: 0.00223004196501014
DOCNO: 14529309
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: radiotherapy
QUALIFIER: therapeutic use
QUALIFIER: methods
AUTHOR: M F Moyers MF
AUTHOR: D W Miller DW
AFFILIATION: Loma Linda University Medical Center, Loma Linda, California 92354, USA. moyers@proton.llumc.edu
PUBTYPE: Journal Article
JOURNALTITLE: Technology in cancer research & treatment.
COUNTRY: United States
TITLE: Range, range modulation, and field radius requirements for proton therapy of prostate cancer.
PUBDATE: 20031001
The Loma Linda University Proton Treatment Facility has treated over 5,000 patients for prostate cancer. Other institutions may find information regarding field size and range requirements for this population of patients useful for designing new proton beamlines. The maximum range, range modulation, and maximum field radius for 240 fields of prostate patients undergoing treatment were sampled and analyzed. Most fields required a range less than 290 mm of water, a modulation width less than or equal to 120 mm, and a radius less than 75 mm.


3. DOCID:30445 SCORE: 0.00218127478313463
DOCNO: 11919208
AUTHOR: F X Bosch FX
AUTHOR: A Lorincz A
AUTHOR: N Muñoz N
AUTHOR: C J L M Meijer CJ
AUTHOR: K V Shah KV
AFFILIATION: Institut Català d'Oncologia, Servei d'Epidemiologia i Registre del Càncer, Gran Via Km 2.7 s/n 08907 L'Hospitalet de Llobregat, 08907 Barcelona, Spain. x.bosch@ico.scs.es
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: Journal of clinical pathology.
COUNTRY: England
TITLE: The causal relation between human papillomavirus and cervical cancer.
PUBDATE: 20020401
The causal role of human papillomavirus infections in cervical cancer has been documented beyond reasonable doubt. The association is present in virtually all cervical cancer cases worldwide. It is the right time for medical societies and public health regulators to consider this evidence and to define its preventive and clinical implications. A comprehensive review of key studies and results is presented.


4. DOCID:29647 SCORE: 0.00212002717432058
DOCNO: 14607373
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: methods
QUALIFIER: methods
QUALIFIER: methods
AUTHOR: Deborah McCaffrey Boyle DM
AFFILIATION: Banner Good Samaritan Medical Center, 1111 E. McDowell Road, Phoenix, AZ 85006, USA. deborah.boyle@bannerhealth.com
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: Critical reviews in oncology/hematology.
COUNTRY: Ireland
TITLE: Establishing a nursing research agenda in gero-oncology.
PUBDATE: 20031101
Expanding the evidence base of cancer in the elderly is critical to advance the specialty of geriatric oncology nursing. This article will propose topics for nursing investigation relative to prevention and early detection, response to disease and treatment, and psychosocial responses in the elderly at risk for, or having cancer. International considerations for undertaking nursing research with this special population are also described. Current dilemmas requiring investigation and future demographic implications are highlighted.


5. DOCID:31870 SCORE: 0.00209025256479059
DOCNO: 15341784
AUTHOR: Kirsty S Hewitson KS
AUTHOR: Christopher J Schofield CJ
AFFILIATION: Oxford Centre for Molecular Sciences and the Department of Chemistry, Chemistry Research Laboratory, Mansfield Road, Oxford, OX1 3TA, UK. kirsty.hewitson@chem.ox.ac.uk
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: Drug discovery today.
COUNTRY: England
TITLE: The HIF pathway as a therapeutic target.
PUBDATE: 20040801
Hypoxia-inducible factor (HIF) is an alpha,beta-heterodimeric transcription factor that mediates cellular responses to low oxygen concentration via the transcriptional activation of specific genes involved in both tumorogenesis and angiogenesis. Manipulation of the HIF pathway has potential use for the treatment of ischemic disease and cancer. Unlike HIF-beta, which is constitutively expressed, the levels and activity of the HIF-alpha subunit are regulated by processes involving posttranslational hydroxylation, catalyzed by Fe(II)- and 2-oxoglutarate-dependent oxygenases. This review focuses on the HIF pathway as a therapeutic target.


6. DOCID:31964 SCORE: 0.00209024253532927
DOCNO: 15340416
AUTHOR: Steven A Rosenberg SA
AUTHOR: James C Yang JC
AUTHOR: Nicholas P Restifo NP
AFFILIATION: Surgery Branch of the Center for Cancer Research at the National Cancer Institute, Building 10, Room 2B42, 10 Center Drive, MSC 1502 Bethesda, Maryland 20892-1502, USA. sar@mail.nih.gov
PUBTYPE: Journal Article
JOURNALTITLE: Nature medicine.
COUNTRY: United States
TITLE: Cancer immunotherapy: moving beyond current vaccines.
PUBDATE: 20040901
Great progress has been made in the field of tumor immunology in the past decade, but optimism about the clinical application of currently available cancer vaccine approaches is based more on surrogate endpoints than on clinical tumor regression. In our cancer vaccine trials of 440 patients, the objective response rate was low (2.6%), and comparable to the results obtained by others. We consider here results in cancer vaccine trials and highlight alternate strategies that mediate cancer regression in preclinical and clinical models.


7. DOCID:31972 SCORE: 0.00209023794969601
DOCNO: 15349523
OWNER: NLM
STATUS: MEDLINE
DESCRIPTOR: Nephrectomy
QUALIFIER: diagnosis
QUALIFIER: surgery
QUALIFIER: diagnosis
QUALIFIER: surgery
QUALIFIER: diagnosis
QUALIFIER: surgery
AUTHOR: Barry Billings B
AUTHOR: Leon C Hamrick LC
AUTHOR: Anton J Bueschen AJ
AUTHOR: Philip J Kenney PJ
AFFILIATION: Division of Urology, University of Alabama at Birmingham and Saint Vincents Hospital, Birmingham, AL, USA.
PUBTYPE: Case Reports
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: TheScientificWorldJournal [electronic resource].
COUNTRY: United States
TITLE: Coexisting angiomyolipoma and renal cell carcinoma in a kidney of an elderly woman: case report and review of the literature.
PUBDATE: 20040601
Angiomyolipoma is a well described but relatively uncommon benign renal neoplasm composed of varying admixtures of mature adipose tissue, smooth muscle, and thick-walled blood vessels. The incidence of angiomyolipoma is about 0.3% overall. It frequently occurs in patients with tuberous sclerosis. Even more uncommon is the simultaneous occurrence of angiomyolipoma and renal cell cancer in the same kidney in a patient without tuberous sclerosis.


8. DOCID:31883 SCORE: 0.00198482386252887
DOCNO: 15519209
OWNER: NLM
STATUS: MEDLINE
DESCRIPTOR: Extracorporeal Membrane Oxygenation
QUALIFIER: methods
QUALIFIER: complications
QUALIFIER: therapy
AUTHOR: Kyung-Hwan Kim KH
AUTHOR: Jin Hyun Kim JH
AUTHOR: Young Whan Kim YW
AFFILIATION: Department of Thoracic and Cardiovascular Surgery, Seoul National University Hospital, Seoul National University College of Medicine, 28 Yongon-dong, Chongno-gu, Seoul 110-744, South Korea. kkh726@snu.ac.kr
PUBTYPE: Case Reports
PUBTYPE: Journal Article
JOURNALTITLE: European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.
COUNTRY: England
TITLE: Use of extracorporeal membrane oxygenation (ECMO) during whole lung lavage in pulmonary alveolar proteinosis associated with lung cancer.
PUBDATE: 20041101
We describe a case of pulmonary alveolar proteinosis in a male adult with lung cancer. To achieve the successful operation of lung cancer, we used percutaneous veno-venous extracorporeal membrane oxygenation (ECMO) during whole lung lavage (WLL) of the contralateral lung. We performed successful WLL under ECMO support.


9. DOCID:31953 SCORE: 0.00198482268588116
DOCNO: 11790556
OWNER: NLM
STATUS: MEDLINE
DESCRIPTOR: Cell Cycle Proteins
DESCRIPTOR: Repressor Proteins
QUALIFIER: physiology
QUALIFIER: etiology
QUALIFIER: physiology
QUALIFIER: physiology
AUTHOR: Emma S Hickman ES
AUTHOR: M Cristina Moroni MC
AUTHOR: Kristian Helin K
AFFILIATION: European Institute of Oncology, Department of Experimental Oncology, Via Ripamonti 435, 20141 Milan, Italy.
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: Current opinion in genetics & development.
COUNTRY: England
TITLE: The role of p53 and pRB in apoptosis and cancer.
PUBDATE: 20020201
Loss of function of both the p53 pathway and the retinoblastoma protein (pRB) pathway plays a significant role in the development of most human cancers. Loss of pRB results in deregulated cell proliferation and apoptosis, whereas loss of p53 desensitizes cells to checkpoint signals, including apoptosis. In the past two years, mouse genetics and gene expression profiling have led to major advances in our understanding of how the pRB and p53 pathways regulate apoptosis and thus the development of tumours.


10. DOCID:28805 SCORE: 0.00193451164837951
DOCNO: 14763133
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: therapeutic use
QUALIFIER: antagonists & inhibitors
QUALIFIER: drug therapy
QUALIFIER: therapeutic use
AUTHOR: Barbara Fingleton B
AFFILIATION: Vanderbilt University Medical Center, Department of Cancer Biology, 736 Preston Research Building, 23rd and Pierce Avenues, Nashville, TN 37232-6840, USA. barbara.fingleton@Vanderbilt.Edu
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: Current opinion in investigational drugs (London, England : 2000)
COUNTRY: England
TITLE: CMT-3. CollaGenex.
PUBDATE: 20031201
CMT-3 is an orally active matrix metalloprotease inhibitor, and one of a series of inhibitors of multiple proteases and cytokines, under development by CollaGenex. The compound is currently undergoing phase II trials for the potential treatment of cancer, in particular metastatic cancer and HIV-related Kaposi's sarcoma.


11. DOCID:28409 SCORE: 0.0018073257618007
DOCNO: 15648954
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: therapeutic use
QUALIFIER: therapeutic use
QUALIFIER: methods
QUALIFIER: therapeutic use
AUTHOR: Seth Cohen S
AUTHOR: Howard L Kaufman HL
AFFILIATION: Department of Surgery, Columbia University, 177 Fort Washington Avenue, New York, NY 10032, USA.
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: Current opinion in investigational drugs (London, England : 2000)
COUNTRY: England
TITLE: TG-4010 Transgene.
PUBDATE: 20041201
Transgene is developing TG-4010, a second-generation modified vaccinia virus Ankara encoding MUC1 and interleukin-2 for the potential treatment of a variety of cancer types. Phase II trials are underway for non-small-cell lung cancer, metastatic renal cancer and prostate cancer.


12. DOCID:30225 SCORE: 0.00179005625448336
DOCNO: 16496770
OWNER: NLM
STATUS: In-Process
AUTHOR: Zsolt Káposztás Z
AUTHOR: Tamás Tornóczky T
AUTHOR: Péter Horváth Ors P
AFFILIATION: Pécsi Tudományegyetem, Orvostudományi és Egészségtudományi Centrum, Sebészeti Klinika. zsoltk@iseb.pote.hu
PUBTYPE: Journal Article
JOURNALTITLE: Magyar sebészet.
COUNTRY: Hungary
TITLE: [The role of surgery in the treatement of gastric lymphoma]
PUBDATE: 20051001
Less than 5% of gastric malignancies are gastric lymphomas. Treatment attitudes have considerably changed in the past 15 years. The international guidelines emphasize the decreasing importance of surgical treatment. The authors summarize the national guidelines concerning the treatment of gastric MALT lymphomas in the mirror of international literature. In addition, a comparative analysis of patients operated on for gastric cancer and gastric lymphoma at our institute from 1993 until 2002 will also be presented, with a special regard to factors influencing survival.


13. DOCID:30568 SCORE: 0.00179004266537358
DOCNO: 15957965
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: therapeutic use
QUALIFIER: therapeutic use
QUALIFIER: drug therapy
QUALIFIER: drug therapy
AUTHOR: Eric T Wong ET
AFFILIATION: Department of Neurology, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, MA 02215, USA. ewong@bidmc.harvard.edu
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: Expert opinion on pharmacotherapy.
COUNTRY: England
TITLE: Monoclonal antibody therapy for central nervous system lymphomas: an emerging treatment paradigm.
PUBDATE: 20050601
The management of CNS lymphomas is poised for another revolution due to the emergence of therapeutic monoclonal antibodies. As the technology for generating monoclonal antibodies matures and obstacles are solved, therapeutic monoclonal antibodies will play an increasing role in the management of cancer. This article will review the biology of CNS lymphomas, monoclonal antibody technology, limitation of existing chemotherapies and the application of therapeutic monoclonal antibodies for the treatment of CNS lymphomas.


14. DOCID:29962 SCORE: 0.00177974188340087
DOCNO: 16184208
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: therapy
AUTHOR: Meagan Brennan M
AUTHOR: Nicholas Wilcken N
AUTHOR: James French J
AUTHOR: Owen Ung O
AUTHOR: John Boyages J
AFFILIATION: NSW Breast Cancer Institute, Westmead Hospital, New South Wales, Australia. meaganb@bci.org.au
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: Australian family physician.
COUNTRY: Australia
TITLE: Management of early breast cancer--the current approach.
PUBDATE: 20050901
This seventh article in our series on breast disease will focus on what is new in the management of invasive primary breast cancer. Up-to-date information on the key aspects of breast cancer management is presented, including descriptions of the new technique of sentinel lymph node biopsy and the new hormone treatment, aromatase inhibitors. Current trends in surgery for breast cancer and the adjuvant treatments of chemotherapy and radiotherapy are also discussed.